Toward curing neurological autoimmune disorders: Biomarkers, immunological mechanisms, and therapeutic targets
- PMID: 39809275
- DOI: 10.1016/j.neuron.2024.12.006
Toward curing neurological autoimmune disorders: Biomarkers, immunological mechanisms, and therapeutic targets
Abstract
Autoimmune neurology is a rapidly expanding field driven by the discovery of neuroglial autoantibodies and encompassing a myriad of conditions affecting every level of the nervous system. Traditionally, autoantibodies targeting intracellular antigens are considered markers of T cell-mediated cytotoxicity, while those targeting extracellular antigens are viewed as pathogenic drivers of disease. However, recent advances highlight complex interactions between these immune mechanisms, suggesting a continuum of immunopathogenesis. The breakdown of immune tolerance, central to these conditions, is affected by modifiable and non-modifiable risk factors such as genetic predisposition, infections, and malignancy. While significant therapeutic advancements have revolutionized treatment of certain diseases, such as neuromyelitis optica, our understanding of many others, particularly T cell-mediated conditions, remains limited, with fewer treatment options available. Future research should focus on improving effector function modeling and deepening our understanding of the factors influencing immune tolerance, with the goal of providing novel treatment options and improving patient care.
Keywords: autoantibodies; autoimmune neurology; cytotoxic; tolerance breakdown.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests S.R.I. has received honoraria/research support from UCB, Immunovant, MedImmun, Roche, Janssen, Cerebral therapeutics, ADC therapeutics, BioHaven therapeutics, CSL Behring, and ONO Pharma and licensed royalties on patent application WO/2010/046716 entitled “Neurological autoimmune disorders” and has filed two other patents entitled “Diagnostic method and therapy” (WO2019211633 and US app 17/051,930; PCT application WO202189788A1) and “Biomarkers” (WO202189788A1, US App 18/279,624; PCT/GB2022/050614). S.J.P. is a named inventor on patent #9,891,219B2, application #12-573,942, methods for treating neuromyelitis optica (NMO) by administration of Eculizumab to an individual that is AQP4-IgG positive, which has been issued and for which he had received royalties. S.J.P. has received grants or research support from Alexion/Astra Zeneca Rare, Horizon/Amgen, F. Hoffmann-La Roche AG, UCB, and Adimune. Since receiving research funding, S.J.P. has received no personal compensation from these companies. In the event of consultation, all compensation for consulting activities is paid directly to Mayo Clinic as per Mayo Clinic policy. S.J.P. has received personal compensation for consultation for Arialys. C.L.H. and B.D.S.C. have received research support from Adimune.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
